BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2026)

BridgeBio Pharma has reported Receivables - Net for 6 years, with the latest figure at $205.2 million in Q1 2026.

• Quarterly Receivables - Net rose 78.05% year-over-year to $205.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.2 million (up 78.05% YoY) and the FY2025 annual result came in at $139.4 million, up 2853.07% from the prior year.
• Receivables - Net grew to $205.2 million in Q1 2026 per BBIO's latest filing, from $139.4 million in the prior quarter.
• Over five years, Receivables - Net peaked at $235.5 million in Q1 2024 and troughed at $478000.0 in Q3 2024.
• A 5-year average of $58.6 million and a median of $17.1 million in 2022 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net plunged 92.34% in 2024, then surged 24276.15% in 2025.
• Over 5 years, Receivables - Net stood at $17.1 million in 2022, then tumbled by 89.75% to $1.8 million in 2023, then soared by 169.67% to $4.7 million in 2024, then jumped by 2853.07% to $139.4 million in 2025, then jumped by 47.17% to $205.2 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $205.2 million, $139.4 million, and $116.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.